A phase 2 trial of Lundbeck’s alpha-synuclein-targeting drug Lu AF82422 ... which cleared phase 1, but was side-lined for strategic reasons, and also abandoned an alpha-syn gene therapy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback